Phosphatidylinositol 3-kinase isoforms as novel drug targets

Current Drug Targets

Volumn 12, Issue 7, 2011, Pages 1056-1081

  Blajecka, Karolina ^a   Borgström, Anna ^a   Arcaro, Alexandre ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

ATP competitive small molecule inhibitors; Autoimmune and cardiovascular diseases; Cancer; Phosphatidylinositol 3 kinases (PI3Ks)

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (1H INDAZOL 4 YL) 6 (4 METHANESULFONYL 1 PIPERAZINYLMETHYL) 4 MORPHOLINOTHIENO[3,2 D]PYRIMIDINE; 2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 (6 AMINO 9 PURINYLMETHYL) 5 METHYL 3 (2 METHYLPHENYL) 3H QUINAZOLIN 4 ONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; 5 (6 QUINOXALINYLMETHYLENE) 2,4 THIAZOLIDINEDIONE; 9 (1 ANILINOETHYL) 7 METHYL 2 MORPHOLINOPYRIDO[1,2 A]PYRIMIDIN 4 ONE; BGT 226; BKM 120; CAL 101; EPIDERMAL GROWTH FACTOR RECEPTOR; G PROTEIN COUPLED RECEPTOR; GDC 091; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN TYROSINE KINASE; SMALL MOLECULE TRANSPORT AGENT; TG 100115; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; WORTMANNIN; XL 147; XL 765; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE;

ACUTE LEUKEMIA; ALLERGIC ASTHMA; APOPTOSIS; ARTERY THROMBOSIS; ARTICLE; ASTHMA; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; BREAST CANCER; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CAROTID ARTERY INJURY; CELL FUNCTION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; DRUG TARGETING; ENDOMETRIUM CARCINOMA; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GLIOBLASTOMA; GLIOMA; GLOMERULONEPHRITIS; HEAD AND NECK CANCER; HEART INFARCTION; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LOSS OF FUNCTION MUTATION; LUNG SQUAMOUS CELL CARCINOMA; LYMPHOMA; MELANOMA; METABOLIC DISORDER; NEOPLASM; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; PROTEIN FAMILY; RHEUMATOID ARTHRITIS; SHEAR STRESS; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; SYSTEMIC LUPUS ERYTHEMATOSUS; THYROID CANCER;

EID: 79958091431     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945011795677773     Document Type: Article

References (333)

1. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 31; 296: 1655-7.
2. Xu Y, Seet LF, Hanson B, et al. The Phox homology (PX) domain, a new player in phosphoinositide signalling. Biochem J 2001; 15; 360: 513-30.
3. Lemmon MA. Pleckstrin homology (PH) domains and phosphoinositides. Biochem Soc Symp 2007; (74): 81-93.
4. Alessi DR, James SR, Downes CP, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 1997; 7: 261-9.
5. Currie RA, Walker KS, Gray A, et al. Role of phosphatidylinositol 3,4,5-trisphosphate in regulating the activity and localization of 3-phosphoinositide-dependent protein kinase-1. Biochem J 1999; 337: 575-83.
6. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098-101.
7. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998; 15: 3499-511.
8. Nave BT, Ouwens M, Withers DJ, Alessi DR, Shepherd PR. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J 1999; 344: 427-31.
9. Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends Mol Med 2005; 11: 353-61.
10. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001; 15: 807-26.
11. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91: 231-41.
12. Duronio V. The life of a cell: apoptosis regulation by the PI3K/PKB pathway. Biochem J 2008; 415: 333-44.
13. Wang SI, Puc J, Li J, Bruce JN, et al. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 1997; 57: 4183-6.
14. Yokoyama Y, Wan X, Shinohara A, et al. Expression of PTEN and PTEN pseudogene in endometrial carcinoma. Int J Mol Med 2000; 6: 47-50.
15. Alimov A, Li C, Gizatullin R, et al. Somatic mutation and homozygous deletion of PTEN/MMAC1 gene of 10q23 in renal cell carcinoma. Anticancer Res 1999; 19: 3841-6.
16. Celebi JT, Shendrik I, Silvers DN, et al. Identification of PTEN mutations in metastatic melanoma specimens. J Med Genet 2000; 37: 653-7.
17. Saito M, Okamoto A, Kohno T, et al. Allelic imbalance and mutations of the PTEN gene in ovarian cancer. Int J Cancer 2000; 85: 160-5.
18. Dahia PL, Marsh DJ, Zheng Z, et al. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res 1997; 57: 4710-3.
19. Halachmi N, Halachmi S, Evron E, et al. Somatic mutations of the PTEN tumor suppressor gene in sporadic follicular thyroid tumors. Genes Chromosomes Cancer 1998; 23: 239-43.
20. Nakahara Y, Nagai H, Kinoshita T, et al. Mutational analysis of the PTEN/MMAC1 gene in non-Hodgkin's lymphoma. Leukemia 1998; 12: 1277-80.
21. Sakai A, Thieblemont C, Wellmann A, et al. PTEN gene alterations in lymphoid neoplasms. Blood 1998; 92: 3410-5.
22. Kawamura N, Nagai H, Bando K, et al. PTEN/MMAC1 mutations in hepatocellular carcinomas: somatic inactivation of both alleles in tumors. Jpn J Cancer Res 1999; 90: 413-8.
23. Hsieh MC, Lin SF, Shin SJ, et al. Mutation analysis of PTEN/MMAC 1 in sporadic thyroid tumors. Kaohsiung J Med Sci 2000; 16: 9-12.
24. Rhei E, Kang L, Bogomolniy F, et al. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res 1997; 57: 3657-9.
25. Cairns P, Okami K, Halachmi S, et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 1997; 57: 4997-5000.
26. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev 2006; 7: 606-19.
27. Kaplan DR, Whitman M, Schaffhausen B, et al. Common elements in growth factor stimulation and oncogenic transformation: 85 kd phosphoprotein and phosphatidylinositol kinase activity. Cell 1987; 50: 1021-9.
28. Skolnik EY, Margolis B, Mohammadi M, et al. Cloning of PI3 kinase-associated p85 utilizing a novel method for expression/cloning of target proteins for receptor tyrosine kinases. Cell 1991; 65: 83-90.
29. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501.
30. Zhao L, Vogt PK. Class I PI3K in oncogenic cellular transformation. Oncogene 2008; 27: 5486-96.
31. Kang S, Denley A, Vanhaesebroeck B, et al. Oncogenic transformation induced by the p110beta,-gamma, and-delta isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci USA 2006; 103: 1289-94.
32. Katso R, Okkenhaug K, Ahmadi K, et al. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001; 17: 615-75.
33. Graupera M, Guillermet-Guibert J, Foukas LC, et al. Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature 2008; 453: 662-6.
34. Guillermet-Guibert J, Bjorklof K, Salpekar A, et al. The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proc Natl Acad Sci USA 2008; 105: 8292-7.
35. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006; 441: 424-30.
36. Rodriguez-Viciana P, Sabatier C, McCormick F. Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate. Mol Cell Biol 2004; 24: 4943-54.
37. Fruman DA, Cantley LC, Carpenter CL. Structural organization and alternative splicing of the murine phosphoinositide 3-kinase p85 alpha gene. Genomics 1996; 37: 113-21.
38. Antonetti DA, Algenstaedt P, Kahn CR. Insulin receptor substrate 1 binds two novel splice variants of the regulatory subunit of phosphatidylinositol 3-kinase in muscle and brain. Mol Cell Biol 1996; 16: 2195-203.
39. Inukai K, Anai M, Van Breda E, et al. A novel 55-kDa regulatory subunit for phosphatidylinositol 3-kinase structurally similar to p55PIK Is generated by alternative splicing of the p85alpha gene. J Biol Chem 1996; 271: 5317-20.
40. Inukai K, Funaki M, Ogihara T, et al. p85alpha gene generates three isoforms of regulatory subunit for phosphatidylinositol 3-kinase (PI 3-Kinase), p50alpha, p55alpha, and p85alpha, with different PI 3-kinase activity elevating responses to insulin. J Biol Chem 1997; 272: 7873-82.
41. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, et al. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 2010; 11: 329-41.
42. Fantl WJ, Escobedo JA, Martin GA, et al. Distinct phosphotyrosines on a growth factor receptor bind to specific molecules that mediate different signaling pathways. Cell 1992; 69: 413-23.
43. Hiles ID, Otsu M, Volinia S, et al. Phosphatidylinositol 3-kinase: structure and expression of the 110 kd catalytic subunit. Cell 1992; 70: 419-29.
44. Klippel A, Escobedo JA, Fantl WJ, et al. The C-terminal SH2 domain of p85 accounts for the high affinity and specificity of the binding of phosphatidylinositol 3-kinase to phosphorylated plateletderived growth factor beta receptor. Mol Cell Biol 1992; 12: 1451-9.
45. Lavan BE, Kuhne MR, Garner CW, et al. The association of insulin-elicited phosphotyrosine proteins with src homology 2 domains. J Biol Chem 1992; 267: 11631-6.
46. Kapeller R, Prasad KV, Janssen O, et al. Identification of two SH3-binding motifs in the regulatory subunit of phosphatidylinositol 3-kinase. J Biol Chem 1994; 269: 1927-33.
47. Pleiman CM, Hertz WM, Cambier JC. Activation of phosphatidylinositol-3' kinase by Src-family kinase SH3 binding to the p85 subunit. Science 1994; 263: 1609-12.
48. Carpenter CL, Auger KR, Chanudhuri M, et al. Phosphoinositide 3-kinase is activated by phosphopeptides that bind to the SH2 domains of the 85-kDa subunit. J Biol Chem 1993; 268: 9478-83.
49. Hui RC, Gomes AR, Constantinidou D, et al. The forkhead transcription factor FOXO3a increases phosphoinositide-3 kinase/Akt activity in drug-resistant leukemic cells through induction of PIK3CA expression. Mol Cell Biol 2008; 28: 5886-98.
50. Yang N, Huang J, Greshock J, et al. Transcriptional regulation of PIK3CA oncogene by NF-kappaB in ovarian cancer microenvironment. PLoS One 2008; 3: e1758.
51. Astanehe A, Arenillas D, Wasserman WW, et al. Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer. J Cell Sci 2008; 121: 664-74.
52. Kok K, Geering B, Vanhaesebroeck B. Regulation of phosphoinositide 3-kinase expression in health and disease. Trends Biochem Sci 2009; 34: 115-27.
53. Dhand R, Hiles I, Panayotou G, et al. PI3-kinase is a dual specificity enzyme: autoregulation by an intrinsic protein-serine kinase activity. Embo J 1994; 13: 522-33.
54. El Sheikh SS, Domin J, Tomtitchong P, et al. Topographical expression of class IA and class II phosphoinositide 3-kinase enzymes in normal human tissues is consistent with a role in differentiation. BMC Clin Pathol 2003; 3: 4.
55. Li Z, Jiang H, Xie W, et al. Roles of PLC-beta2 and-beta3 and PI3Kgamma in chemoattractant-mediated signal transduction. Science 2000; 287: 1046-9.
56. Vanhaesebroeck B, Welham MJ, Kotani K, et al. P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci USA 1997; 94: 4330-5.
57. Chantry D, Vojtek A, Kashishian A, et al. p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J Biol Chem 1997; 272: 19236-41.
58. Eickholt BJ, Ahmed AI, Davies M, et al. Control of axonal growth and regeneration of sensory neurons by the p110delta PI 3-kinase. PLoS One 2007; 2: e869.
59. Stephens LR, Eguinoa A, Erdjument-Bromage H, et al. The G beta gamma sensitivity of a PI3K is dependent upon a tightly associated adaptor, p101. Cell 1997; 89: 105-14.
60. Suire S, Coadwell J, Ferguson GJ, et al. p84, a new Gbetagammaactivated regulatory subunit of the type IB phosphoinositide 3-kinase p110gamma. Curr Biol 2005; 15: 566-70.
61. Voigt P, Dorner MB, Schaefer M. Characterization of p87PIKAP, a novel regulatory subunit of phosphoinositide 3-kinase gamma that is highly expressed in heart and interacts with PDE3B. J Biol Chem 2006; 281: 9977-86.
62. Bohnacker T, Marone R, Collmann E, et al. PI3Kgamma adaptor subunits define coupling to degranulation and cell motility by distinct PtdIns(3,4,5)P3 pools in mast cells. Sci Signal 2009; 2: ra27.
63. Wymann MP, Bjorklof K, Calvez R, et al. Phosphoinositide 3-kinase gamma: a key modulator in inflammation and allergy. Biochem Soc Trans 2003; 31: 275-80.
64. Brock C, Schaefer M, Reusch HP, et al. Roles of G beta gamma in membrane recruitment and activation of p110 gamma/p101 phosphoinositide 3-kinase gamma. J Cell Biol 2003; 160: 89-99.
65. Leopoldt D, Hanck T, Exner T, et al. Gbetagamma stimulates phosphoinositide 3-kinase-gamma by direct interaction with two domains of the catalytic p110 subunit. J Biol Chem 1998; 273: 7024-9.
66. Maier U, Babich A, Nurnberg B. Roles of non-catalytic subunits in gbetagamma-induced activation of class I phosphoinositide 3-kinase isoforms beta and gamma. J Biol Chem 1999; 274: 29311-7.
67. Krugmann S, Cooper MA, Williams DH, et al. Mechanism of the regulation of type IB phosphoinositide 3OH-kinase byG-protein betagamma subunits. Biochem J 2002; 362: 725-31.
68. Suire S, Hawkins P, Stephens L. Activation of phosphoinositide 3-kinase gamma by Ras. Curr Biol 2002; 12: 1068-75.
69. Virbasius JV, Guilherme A, Czech MP. Mouse p170 is a novel phosphatidylinositol 3-kinase containing a C2 domain. J Biol Chem 1996; 271: 13304-7.
70. MacDougall LK, Domin J, Waterfield MD. A family of phosphoinositide 3-kinases in Drosophila identifies a new mediator of signal transduction. Curr Biol 1995; 5: 1404-15.
71. Wheeler M, Domin J. Recruitment of the class II phosphoinositide 3-kinase C2beta to the epidermal growth factor receptor: role of Grb2. Mol Cell Biol 2001; 21: 6660-7.
72. Brown RA, Ho LK, Weber-Hall SJ, et al. Identification and cDNA cloning of a novel mammalian C2 domain-containing phosphoinositide 3-kinase, HsC2-PI3K. Biochem Biophys Res Commun 1997; 233: 537-44.
73. Maffucci T, Cooke FT, Foster FM, et al. Class II phosphoinositide 3-kinase defines a novel signaling pathway in cell migration. J Cell Biol 2005; 169: 789-99.
74. Katso RM, Pardo OE, Palamidessi A, et al. Phosphoinositide 3-Kinase C2beta regulates cytoskeletal organization and cell migration via Rac-dependent mechanisms. Mol Biol Cell 2006; 17: 3729-44.
75. Falasca M, Hughes WE, Dominguez V, et al. The role of phosphoinositide 3-kinase C2alpha in insulin signaling. J Biol Chem 2007; 282: 28226-36.
76. Zhao Y, Gaidarov I, Keen JH. Phosphoinositide 3-kinase C2alpha links clathrin to microtubule-dependent movement. J Biol Chem 2007; 282: 1249-56.
77. Domin J, Gaidarov I, Smith ME, et al. The class II phosphoinositide 3-kinase PI3K-C2alpha is concentrated in the trans-Golgi network and present in clathrin-coated vesicles. J Biol Chem 2000; 275: 11943-50.
78. Gaidarov I, Smith ME, Domin J, et al. The class II phosphoinositide 3-kinase C2alpha is activated by clathrin and regulates clathrin-mediated membrane trafficking. Mol Cell 2001; 7: 443-9.
79. Yu W, Sun X, Tang H, et al. Inhibition of class II phosphoinositide 3-kinase gamma expression by p185(Bcr-Abl) contributes to impaired chemotaxis and aberrant homing of leukemic cells. Leuk Lymphoma 2010; 51: 1098-107.
80. Hickinson DM, Lucocq JM, Towler MC, et al. Association of a phosphatidylinositol-specific 3-kinase with a human trans-Golgi network resident protein. Curr Biol 1997; 7: 987-90.
81. Byfield MP, Murray JT, Backer JM. hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase. J Biol Chem 2005; 280: 33076-82.
82. Nobukuni T, Joaquin M, Roccio M, et al. Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc Natl Acad Sci USA 2005; 102: 14238-43.
83. Slessareva JE, Routt SM, Temple B, et al. Activation of the phosphatidylinositol 3-kinase Vps34 by a G protein alpha subunit at the endosome. Cell 2006; 126: 191-203.
84. Kihara A, Noda T, Ishihara N, et al. Two distinct Vps34 phosphatidylinositol 3-kinase complexes function in autophagy and carboxypeptidase Y sorting in Saccharomyces cerevisiae. J Cell Biol 2001; 152: 519-30.
85. Petiot A, Ogier-Denis E, Blommaart EF, et al. Distinct classes of phosphatidylinositol 3'-kinases are involved in signaling pathways that control macroautophagy in HT-29 cells. J Biol Chem 2000; 275: 992-8.
86. Kihara A, Kabeya Y, Ohsumi Y, et al. Beclin-phosphatidylinositol 3-kinase complex functions at the trans-Golgi network. EMBO Rep 2001; 2: 330-5.
87. Workman P, van Montfort RL, et al. Unveiling the secrets of the ancestral PI3 kinase Vps34. Cancer Cell 2010; 17: 421-3.
88. Kondo Y, Kanzawa T, Sawaya R, et al. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 2005; 5: 726-34.
89. Wu J, Randle KE, Wu LP. ird1 is a Vps15 homologue important for antibacterial immune responses in Drosophila. Cell Microbiol 2007; 9: 1073-85.
90. Roggo L, Bernard V, Kovacs AL, et al. Membrane transport in Caenorhabditis elegans: an essential role for VPS34 at the nuclear membrane. EMBO J 2002; 21: 1673-83.
91. Stopkova P, Saito T, Papolos DF, et al. Identification of PIK3C3 promoter variant associated with bipolar disorder and schizophrenia. Biol Psychiatry 2004; 55: 981-8.
92. Saito T, Aghalar MR, Lachman HM. Analysis of PIK3C3 promoter variant in African-Americans with schizophrenia. Schizophr Res 2005; 76: 361-2.
93. Backer JM. The regulation and function of Class III PI3Ks: novel roles for Vps34. Biochem J 2008; 410: 1-17.
94. Huang J, Klionsky DJ. Autophagy and human disease. Cell Cycle 2007; 6: 1837-49.
95. Vanhaesebroeck B, Ali K, Bilancio A, et al. Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci 2005; 30: 194-204.
96. Cheng CK, Fan QW, Weiss WA. PI3K signaling in glioma--animal models and therapeutic challenges. Brain Pathol 2009; 19: 112-20.
97. Bi L, Okabe I, Bernard DJ, et al. Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase. Mamm Genome 2002; 13: 169-72.
98. Bi L, Okabe I, Bernard DJ, et al. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase. J Biol Chem 1999; 274: 10963-8.
99. Sasaki T, Irie-Sasaki J, Horie Y, et al. Colorectal carcinomas in mice lacking the catalytic subunit of PI(3)Kgamma. Nature 2000; 406: 897-902.
100. Jou ST, Carpino N, Takahashi Y, et al. Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. Mol Cell Biol 2002; 22: 8580-91.
101. Okkenhaug K, Bilancio A, Farjot G, et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 2002; 297: 1031-4.
102. Brachmann SM, Ueki K, Engelman JA, et al. Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice. Mol Cell Biol 2005; 25: 1596-607.
103. Foukas LC, Claret M, Pearce W, et al. Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 2006; 441: 366-70.
104. Knight ZA, Gonzalez B, Feldman ME, et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 2006; 125: 733-47.
105. Ciraolo E, Iezzi M, Marone R, et al. Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development. Sci Signal 2008; 1: ra3.
106. Jia S, Liu Z, Zhang S, et al. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 2008; 454: 776-9.
107. Jou ST, Carpino N, Takahashi Y, et al. Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. Mol Cell Biol 2002; 22: 8580-91.
108. Bilancio A, Okkenhaug K, Camps M, et al. Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells. Blood 2006; 107: 642-50.
109. Al-Alwan MM, Okkenhaug K, Vanhaesebroeck B, et al. Requirement for phosphoinositide 3-kinase p110delta signaling in B cell antigen receptor-mediated antigen presentation. J Immunol 2007; 178: 2328-35.
110. Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol 2003; 3: 317-30.
111. Okkenhaug K, Vanhaesebroeck B. PI3K-signalling in B-and Tcells: insights from gene-targeted mice. Biochem Soc Trans 2003; 31: 270-4.
112. Webb LM, Vigorito E, Wymann MP, et al. Cutting edge: T cell development requires the combined activities of the p110gamma and p110delta catalytic isoforms of phosphatidylinositol 3-kinase. J Immunol 2005; 175: 2783-7.
113. Hirsch E, Katanaev VL, Garlanda C, et al. Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science 2000; 287: 1049-53.
114. Rickert P, Weiner OD, Wang F, et al. Leukocytes navigate by compass: roles of PI3Kgamma and its lipid products. Trends Cell Biol 2000; 10: 466-73.
115. Sasaki T, Irie-Sasaki J, Jones RG, et al. Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science 2000; 287: 1040-6.
116. Stephens L, Ellson C, Hawkins P. Roles of PI3Ks in leukocyte chemotaxis and phagocytosis. Curr Opin Cell Biol 2002; 14: 203-13.
117. Terauchi Y, Tsuji Y, Satoh S, et al. Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase. Nat Genet 1999; 21: 230-5.
118. Fruman DA, Snapper SB, Yballe CM, et al. Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha. Science 1999; 283: 393-7.
119. Fruman DA, Mauvais-Jarvis F, Pollard DA, et al. Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85 alpha. Nat Genet 2000; 26: 379-82.
120. Ueki K, Fruman DA, Brachmann SM, et al. Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. Mol Cell Biol 2002; 22: 965-77.
121. Ueki K, Yballe CM, Brachmann SM, et al. Increased insulin sensitivity in mice lacking p85beta subunit of phosphoinositide 3-kinase. Proc Natl Acad Sci USA 2002; 99: 419-24.
122. Ueki K, Fruman DA, Yballe CM, et al. Positive and negative roles of p85 alpha and p85 beta regulatory subunits of phosphoinositide 3-kinase in insulin signaling. J Biol Chem 2003; 278: 48453-66.
123. Luo J, Cantley LC. The negative regulation of phosphoinositide 3-kinase signaling by p85 and it's implication in cancer. Cell Cycle 2005; 4: 1309-12.
124. Zhao JJ, Cheng H, Jia S, et al. The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proc Natl Acad Sci USA 2006; 103: 16296-300.
125. Suire S, Condliffe AM, Ferguson GJ, et al. Gbetagammas and the Ras binding domain of p110gamma are both important regulators of PI(3)Kgamma signalling in neutrophils. Nat Cell Biol 2006; 8: 1303-9.
126. Borlado LR, Redondo C, Alvarez B, et al. Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo. FASEB J 2000; 14: 895-903.
127. Holland EC, Celestino J, Dai C, et al. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 2000; 25: 55-7.
128. Hallmann D, Trumper K, Trusheim H, et al. Altered signaling and cell cycle regulation in embryonal stem cells with a disruption of the gene for phosphoinositide 3-kinase regulatory subunit p85alpha. J Biol Chem 2003; 278: 5099-108.
129. Suzuki H, Terauchi Y, Fujiwara M, et al. Xid-like immunodeficiency in mice with disruption of the p85alpha subunit of phosphoinositide 3-kinase. Science 1999; 283: 390-2.
130. Mauvais-Jarvis F, Ueki K, Fruman DA, et al. Reduced expression of the murine p85alpha subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. J Clin Invest 2002; 109: 141-9.
131. Chen D, Mauvais-Jarvis F, Bluher M, et al. p50alpha/p55alpha phosphoinositide 3-kinase knockout mice exhibit enhanced insulin sensitivity. Mol Cell Biol 2004; 24: 320-9.
132. Zhao JJ, Roberts TM. PI3 kinases in cancer: from oncogene artifact to leading cancer target. Sci STKE 2006; 2006: pe52.
133. Sugimoto Y, Whitman M, Cantley LC, et al. Evidence that the Rous sarcoma virus transforming gene product phosphorylates phosphatidylinositol and diacylglycerol. Proc Natl Acad Sci USA 1984; 81: 2117-21.
134. Whitman M, Downes CP, Keeler M, et al. Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. Nature 1988; 332: 644-6.
135. Whitman M, Kaplan DR, Schaffhausen B, et al. Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation. Nature 1985; 315: 239-42.
136. Markman B, Atzori F, Perez-Garcia J, et al. Status of PI3K inhibition and biomarker development in cancer therapeutics. Ann Oncol 2009; 21: 683-91.
137. Philp AJ, Campbell IG, Leet C, et al. The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res 2001; 61: 7426-9.
138. Mizoguchi M, Nutt CL, Mohapatra G, et al. Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas. Brain Pathol 2004; 14: 372-7.
139. Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 2004; 3: 1221-4.
140. Ikenoue T, Kanai F, Hikiba Y, et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 2005; 65: 4562-7.
141. Campbell IG, Russell SE, Choong DY, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004; 64: 7678-81.
142. Kang S, Seo SS, Chang HJ, et al. Mutual exclusiveness between PIK3CA and KRAS mutations in endometrial carcinoma. Int J Gynecol Cancer 2008; 18: 1339-43.
143. Massion PP, Kuo WL, Stokoe D, et al. Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res 2002; 62: 3636-40.
144. Lee JW, Soung YH, Kim SY, et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005; 24: 1477-80.
145. Pedrero JM, Carracedo DG, Pinto CM, et al. Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer 2005; 114: 242-8.
146. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008; 68: 6084-91.
147. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554.
148. Velho S, Oliveira C, Ferreira A, et al. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 2005; 41: 1649-54.
149. Huang CH, Mandelker D, Schmidt-Kittler O, et al. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science 2007; 318: 1744-8.
150. Miled N, Yan Y, Hon WC, et al. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 2007; 317: 239-42.
151. Catalouge of somatic mutations in cancer. Available at: http://www.sanger.ac.uk/genetics/CGP/cosmic/ [accessed July 6, 2010].
152. Gymnopoulos M, Elsliger MA, Vogt PK. Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci USA 2007; 104: 5569-74.
153. Benistant C, Chapuis H, Roche S. A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alphap110beta) in de novo DNA synthesis of human colon carcinoma cells. Oncogene 2000; 19: 5083-90.
154. Knobbe CB, Reifenberger G. Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3'-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol 2003; 13: 507-18.
155. Courtney KD, Corcoran RB, Engelman JA. The PI3K Pathway As Drug Target in Human Cancer. J Clin Oncol 2010; 28: 1075-83.
156. Boller D, Schramm A, Doepfner KT, et al. Targeting the phosphoinositide 3-kinase isoform p110delta impairs growth and survival in neuroblastoma cells. Clin Cancer Res 2008; 14: 1172-81.
157. Doepfner KT, Spertini O, Arcaro A. Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway. Leukemia 2007; 21: 1921-30.
158. Sujobert P, Bardet V, Cornillet-Lefebvre P, et al. Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 2005; 106: 1063-6.
159. Knobbe CB, Trampe-Kieslich A, Reifenberger G. Genetic alteration and expression of the phosphoinositol-3-kinase/Akt pathway genes PIK3CA and PIKE in human glioblastomas. Neuropathol Appl Neurobiol 2005; 31: 486-90.
160. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007; 318: 1108-13.
161. Jaiswal BS, Janakiraman V, Kljavin NM, et al. Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell 2009; 16: 463-74.
162. Carpten JD, Faber AL, Horn C, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007; 448: 439-44.
163. Kim MS, Jeong EG, Yoo NJ, et al. Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. Br J Cancer 2008; 98: 1533-5.
164. Malanga D, Scrima M, De Marco C, et al. Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle 2008; 7: 665-9.
165. Tibes R, Kornblau SM, Qiu Y, et al. PI3K/AKT pathway activation in acute myeloid leukaemias is not associated with AKT1 pleckstrin homology domain mutation. Br J Haematol 2008; 140: 344-7.
166. Mahmoud IS, Sughayer MA, Mohammad HA, et al. The transforming mutation E17K/AKT1 is not a major event in B-cellderived lymphoid leukaemias. Br J Cancer 2008; 99: 488-90.
167. Soung YH, Lee JW, Nam SW, et al. Mutational analysis of AKT1, AKT2 and AKT3 genes in common human carcinomas. Oncology 2006; 70: 285-9.
168. Davies MA, Stemke-Hale K, Tellez C, et al. A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer 2008; 99: 1265-8.
169. Staal SP. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci USA 1987; 84: 5034-7.
170. Brugge J, Hung MC, Mills GB. A new mutational AKTivation in the PI3K pathway. Cancer Cell 2007; 12: 104-7.
171. Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007; 12: 395-402.
172. Zunder ER, Knight ZA, Houseman BT, et al. Discovery of drugresistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha. Cancer Cell 2008; 14: 180-92.
173. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6: 117-27.
174. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004; 22: 2954-63.
175. Engelman JA, Mukohara T, Zejnullahu K, et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest 2006; 116: 2695-706.
176. Parsons DW, Wang TL, Samuels Y, et al. Colorectal cancer: mutations in a signalling pathway. Nature 2005; 436: 792.
177. Ma YY, Wei SJ, Lin YC, et al. PIK3CA as an oncogene in cervical cancer. Oncogene 2000; 19: 2739-44.
178. Wu G, Mambo E, Guo Z, et al. Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab 2005; 90: 4688-93.
179. Byun DS, Cho K, Ryu BK, et al. Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma. Int J Cancer 2003; 104: 318-27.
180. Harris SJ, Foster JG, Ward SG. PI3K isoforms as drug targets in inflammatory diseases: lessons from pharmacological and genetic strategies. Curr Opin Investig Drugs 2009; 10: 1151-62.
181. Ghigo A, Damilano F, Braccini L, et al. PI3K inhibition in inflammation: Toward tailored therapies for specific diseases. Bioessays 2010; 32: 185-96.
182. Condliffe AM, Davidson K, Anderson KE, et al. Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood 2005; 106: 1432-40.
183. Ali K, Camps M, Pearce WP, et al. Isoform-specific functions of phosphoinositide 3-kinases: p110 delta but not p110 gamma promotes optimal allergic responses in vivo. J Immunol 2008; 180: 2538-44.
184. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008; 358: 929-39.
185. Wakeland EK, Liu K, Graham RR, et al. Delineating the genetic basis of systemic lupus erythematosus. Immunity 2001; 15: 397-408.
186. Isenberg DA, Manson JJ, Ehrenstein MR, et al. Fifty years of antids DNA antibodies: are we approaching journey's end? Rheumatology 2007; 46: 1052-6.
187. Barber DF, Bartolome A, Hernandez C, et al. PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat Med 2005; 11: 933-5.
188. Barber DF, Bartolome A, Hernandez C, et al. Class IBphosphatidylinositol 3-kinase (PI3K) deficiency ameliorates IAPI3K-induced systemic lupus but not T cell invasion. J Immunol 2006; 176: 589-93.
189. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003; 2: 473-88.
190. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003; 423: 356-61.
191. Camps M, Ruckle T, Ji H, et al. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 2005; 11: 936-43.
192. Hayer S, Pundt N, Peters MA, et al. PI3Kgamma regulates cartilage damage in chronic inflammatory arthritis. FASEB J 2009; 23: 4288-98.
193. Randis TM, Puri KD, Zhou H, et al. Role of PI3Kdelta and PI3Kgamma in inflammatory arthritis and tissue localization of neutrophils. Eur J Immunol 2008; 38: 1215-24.
194. Busse WW, Lemanske RF, Jr. Asthma. N Engl J Med 2001; 344: 350-62.
195. Takeda M, Ito W, Tanabe M, et al. The pathophysiological roles of PI3Ks and therapeutic potential of selective inhibitors in allergic inflammation. Int Arch Allergy Immunol 2010; 152 Suppl 1: 90-5.
196. Park SJ, Min KH, Lee YC. Phosphoinositide 3-kinase delta inhibitor as a novel therapeutic agent in asthma. Respirology 2008; 13: 764-71.
197. Nashed BF, Zhang T, Al-Alwan M, et al. Role of the phosphoinositide 3-kinase p110delta in generation of type 2 cytokine responses and allergic airway inflammation. Eur J Immunol 2007; 37: 416-24.
198. Lee KS, Lee HK, Hayflick JS, et al. Inhibition of phosphoinositide 3-kinase delta attenuates allergic airway inflammation and hyperresponsiveness in murine asthma model. FASEB J 2006; 20: 455-65.
199. Ali K, Bilancio A, Thomas M, et al. Essential role for the p110delta phosphoinositide 3-kinase in the allergic response. Nature 2004; 431: 1007-11.
200. Lim DH, Cho JY, Song DJ, Lee SY, Miller M, Broide DH. PI3K gamma-deficient mice have reduced levels of allergen-induced eosinophilic inflammation and airway remodeling. Am J Physiol Lung Cell Mol Physiol 2009; 296: L210-9.
201. Takeda M, Ito W, Tanabe M, et al. Allergic airway hyperresponsiveness, inflammation, and remodeling do not develop in phosphoinositide 3-kinase gamma-deficient mice. J Allergy Clin Immunol 2009; 123: 805-12.
202. Doherty DE. The pathophysiology of airway dysfunction. Am J Med 2004; 117 (Suppl 12A): 11S-23S.
203. Doukas J, Eide L, Stebbins K, et al. Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. J Pharmacol Exp Ther 2009; 328: 758-65.
204. Kundu JK, Surh YJ. Inflammation: gearing the journey to cancer. Mutat Res 2008; 659: 15-30.
205. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006; 6: 508-19.
206. Woollard KJ, Geissmann F. Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol 2010; 7: 77-86.
207. Biwa T, Sakai M, Matsumura T, et al. Sites of action of protein kinase C and phosphatidylinositol 3-kinase are distinct in oxidized low density lipoprotein-induced macrophage proliferation. J Biol Chem 2000; 275: 5810-6.
208. Martens JS, Reiner NE, Herrera-Velit P, Steinbrecher UP. Phosphatidylinositol 3-kinase is involved in the induction of macrophage growth by oxidized low density lipoprotein. J Biol Chem 1998; 273: 4915-20.
209. Chang JD, Sukhova GK, Libby P, et al. Deletion of the phosphoinositide 3-kinase p110gamma gene attenuates murine atherosclerosis. Proc Natl Acad Sci USA 2007; 104: 8077-82.
210. Fougerat A, Gayral S, Gourdy P, et al. Genetic and pharmacological targeting of phosphoinositide 3-kinase-gamma reduces atherosclerosis and favors plaque stability by modulating inflammatory processes. Circulation 2008; 117: 1310-7.
211. Frangogiannis NG. The immune system and cardiac repair. Pharmacol Res 2008; 58: 88-111.
212. Nah DY, Rhee MY. The inflammatory response and cardiac repair after myocardial infarction. Korean Circ J 2009; 39: 393-8.
213. Doukas J, Wrasidlo W, Noronha G, et al. Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury. Proc Natl Acad Sci USA 2006; 103: 19866-71.
214. Oudit GY, Penninger JM. Cardiac regulation by phosphoinositide 3-kinases and PTEN. Cardiovasc Res 2009; 82: 250-60.
215. Owen KL, Pretorius L, McMullen JR. The protective effects of exercise and phosphoinositide 3-kinase (p110alpha) in the failing heart. Clin Sci 2009; 116: 365-75.
216. Damilano F, Perino A, Hirsch E. PI3K kinase and scaffold functions in heart. Ann N Y Acad Sci 2010; 1188: 39-45.
217. Crackower MA, Oudit GY, Kozieradzki I, et al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 2002; 110: 737-49.
218. Shioi T, Kang PM, Douglas PS, et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J 2000; 19: 2537-48.
219. Shioi T, McMullen JR, Kang PM, et al. Akt/protein kinase B promotes organ growth in transgenic mice. Mol Cell Biol 2002; 22: 2799-809.
220. Luo J, McMullen JR, Sobkiw CL, et al. Class IA phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy. Mol Cell Biol 2005; 25: 9491-502.
221. McMullen JR, Shioi T, Huang WY, et al. The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110alpha) pathway. J Biol Chem 2004; 279: 4782-93.
222. Naga Prasad SV, Esposito G, Mao L, Koch WJ, Rockman HA. Gbetagamma-dependent phosphoinositide 3-kinase activation in hearts with in vivo pressure overload hypertrophy. J Biol Chem 2000; 275: 4693-8.
223. Wang Y. Mitogen-activated protein kinases in heart development and diseases. Circulation 2007; 116: 1413-23.
224. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 2006; 7: 589-600.
225. Patrucco E, Notte A, Barberis L, et al. PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinasedependent and-independent effects. Cell 2004; 118: 375-87.
226. Naga Prasad SV, Barak LS, Rapacciuolo A, Caron MG, Rockman HA. Agonist-dependent recruitment of phosphoinositide 3-kinase to the membrane by beta-adrenergic receptor kinase 1. A role in receptor sequestration. J Biol Chem 2001; 276: 18953-9.
227. Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembranespanning receptors and heart function. Nature 2002; 415: 206-12.
228. Naga Prasad SV, Jayatilleke A, Madamanchi A, Rockman HA. Protein kinase activity of phosphoinositide 3-kinase regulates betaadrenergic receptor endocytosis. Nat Cell Biol 2005; 7: 785-96.
229. Jackson SF, Schoenwaelder SM. Type I phosphoinositide 3-kinases: potential antithrombotic targets? Cell Mol Life Sci 2006; 63: 1085-90.
230. Hirsch E, Bosco O, Tropel P, et al. Resistance to thromboembolism in PI3Kgamma-deficient mice. FASEB J 2001; 15: 2019-21.
231. Lian L, Wang Y, Draznin J, et al. The relative role of PLCbeta and PI3Kgamma in platelet activation. Blood 2005; 106: 110-7.
232. Jackson SP, Schoenwaelder SM, Goncalves I, et al. PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med 2005; 11: 507-14.
233. Jackson SP, Schoenwaelder SM. Antiplatelet therapy: in search of the 'magic bullet'. Nat Rev Drug Discov 2003; 2: 775-89.
234. Yap CL, Anderson KE, Hughan SC, Dopheide SM, Salem HH, Jackson SP. Essential role for phosphoinositide 3-kinase in sheardependent signaling between platelet glycoprotein Ib/V/IX and integrin alpha(IIb)beta(3). Blood 2002; 99: 151-8.
235. Goncalves I, Hughan SC, Schoenwaelder SM, Yap CL, Yuan Y, Jackson SP. Integrin alpha IIb beta 3-dependent calcium signals regulate platelet-fibrinogen interactions under flow. Involvement of phospholipase C gamma 2. J Biol Chem 2003; 278: 34812-22.
236. Petersen KF, Shulman GI. Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus. Am J Cardiol 2002; 90: 11G-8G.
237. Marone R, Cmiljanovic V, Giese B, Wymann MP. Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta 2008; 1784: 159-85.
238. Morisco C, Lembo G, Trimarco B. Insulin resistance and cardiovascular risk: New insights from molecular and cellular biology. Trends Cardiovasc Med 2006; 16: 183-8.
239. Cong LN, Chen H, Li Y, et al. Physiological role of Akt in insulinstimulated translocation of GLUT4 in transfected rat adipose cells. Mol Endocrinol 1997; 11: 1881-90.
240. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 2006; 7: 85-96.
241. Sano H, Kane S, Sano E, et al. Insulin-stimulated phosphorylation of a Rab GTPase-activating protein regulates GLUT4 translocation. J Biol Chem 2003; 278: 14599-602.
242. Choi K, Kim YB. Molecular mechanism of insulin resistance in obesity and type 2 diabetes. Korean J Intern Med 2010; 25: 119-29.
243. Tremblay FDR, Lavigne C, Jacques HLN, Marette A. Defective insulin-induced GLUT4 translocation in skeletal muscle of high fat-fed rats is associated with alterations in both Akt/Protein Kinase B and Atypical Protein Kinase C (ζ/λ) activities. Diabetes 2001; 50: 1901-10.
244. Taniguchi CM, Tran TT, Kondo T, et al. Phosphoinositide 3-kinase regulatory subunit p85alpha suppresses insulin action via positive regulation of PTEN. Proc Natl Acad Sci USA 2006; 103: 12093-7.
245. Barroso I, Luan J, Middelberg RP, et al. Candidate gene association study in type 2 diabetes indicates a role for genes involved in beta-cell function as well as insulin action. PLoS Biol 2003; 1: E20.
246. Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res 2000; 6: 880-6.
247. Ihle NT, Williams R, Chow S, et al. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol Cancer Ther 2004; 3: 763-72.
248. Schwertschlag US, Chiorean EG, Anthony SP, et al. Phase 1 pharmacokinetic (PK) and pharmacodynamic(PD) evaluation of SF1126 a vascular targeted pan phosphoinositide 3-kinase (PI3K) inhibitor in patients with solid tumors. J Clin Oncol (Meeting Abstracts) 2008; 26 (15S): 14532.
249. Garlich JR, De P, Dey N, et al. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res 2008; 68: 206-15.
250. Chiorean EG, Mahadevan D, Harris WB, et al. Phase I evaluation of SF1126, a vascular targeted PI3K inhibitor, administered twice weekly IV in patients with refractory solid tumors. J Clin Oncol (Meeting Abstracts) 2009; 27(15S): 2558.
251. A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors (SF112600106). Available at: http://www.clinicaltrials.gov/ ct2/ show/NCT00907205?term=SF1126&rank=1 [accessed June 24, 2010].
252. Raynaud FI, Eccles S, Clarke PA, et al. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 2007; 67: 5840-50.
253. Fan QW, Knight ZA, Goldenberg DD, et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006; 9: 341-9.
254. Kharas MG, Janes MR, Scarfone VM, et al. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J Clin Invest 2008; 118: 3038-50.
255. Al-Saffar NM, Jackson LE, Raynaud FI, et al. The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase {alpha} leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy. Cancer Res 2010; 70: 5507-17.
256. Folkes AJ, Ahmadi K, Alderton WK, et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 2008; 51: 5522-32.
257. Raynaud FI, Eccles SA, Patel S, et al. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther 2009; 8: 1725-38.
258. O'Brien C, Wallin JJ, Sampath D, et al. Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3' Kinase Inhibitor GDC-0941 In Breast Cancer Preclinical Models. Clin Cancer Res 2010; 16: 3670-83.
259. GDC-0941. Available at: http://www.clinicaltrials.gov/ct2/ results?term=GDC-0941 [accessed June 24, 2010].
260. Baird RD, Kristeleit RS, Sarker D, et al. A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941. J Clin Oncol (Meeting Abstracts) 2010; 28(15_suppl): 2613.
261. Von Hoff DD, LoRusso P, Tibes R, et al. A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts) 2010; 28(15_suppl): 2541.
262. Stauffer F, Maira SM, Furet P, Garcia-Echeverria C. Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway. Bioorg Med Chem Lett 2008; 18: 1027-30.
263. Maira SM, Stauffer F, Brueggen J, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008; 7: 1851-63.
264. Serra V, Markman B, Scaltriti M, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008; 68: 8022-30.
265. Manara MC, Nicoletti G, Zambelli D, et al. NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res 2010; 16: 530-40.
266. Brachmann SM, Hofmann I, Schnell C, et al. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci USA 2009; 106: 22299-304.
267. Schnell CR, Stauffer F, Allegrini PR, et al. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res 2008; 68: 6598-607.
268. McMillin DW, Ooi M, Delmore J, et al. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res 2009; 69: 5835-42.
269. Baumann P, Mandl-Weber S, Oduncu F, Schmidmaier R. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma. Exp Cell Res 2009; 315: 485-97.
270. Cao P, Maira SM, Garcia-Echeverria C, Hedley DW. Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. Br J Cancer 2009; 100: 1267-76.
271. Cho DC, Cohen MB, Panka DJ, et al. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res 2010; 16: 3628-38.
272. A phase I/II study of BEZ235 in patients with advanced solid malignancies enriched by patients with advanced breast cancer. Available at: http://www.clinicaltrials.gov/ct2/show/NCT0062059 4?term=BEZ235&rank=1 [accessed June 24, 2010].
273. Burris H, Rodon J, Sharma S, et al. First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors. J Clin Oncol (Meeting Abstracts) 2010; 28(15_suppl): 3005.
274. Stauffer F, Garcia-Echeverria C, Furet P, et al. Biochemical, cellular and in vivo profiling of a new PI3K inhibitor from the imidazoquinoline series. AACR Meeting Abstracts 2007; (1_Annual_Meeting): 269.
275. A phase I/II study of BGT226 in adult patients with advanced solid malignancies including patients with advanced breast cancer. Available at: http://www.clinicaltrials.gov/ct2/show/ NCT0060027 5?term=BGT226&rank=1 [accessed July 4, 2010].
276. Safety of BKM120 monotherapy in advanced solid tumor patients. Available at: http://clinicaltrials.gov/ct2/show/NCT01068483?term=BKM120&r ank=1 [accessed July 4, 2010].
277. Baselga J, De Jonge MJ, Rodon J, et al. A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors. J Clin Oncol (Meeting Abstracts) 2010; 28(15_suppl): 3003-.
278. Edelman G, Bedell C, Shapiro G, et al. A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies. J Clin Oncol (Meeting Abstracts) 2010; 28(15_suppl): 3004-.
279. Foster P. Potentiating the antitumor effects of chemotherapy with the selective PI3K inhibitor XL147. AACR Meeting Abstracts 2007; (3_Molecular_Targets_Meeting): C199.
280. Shapiro G, Edelman G, Calvo E, Aggarwal S, Laird A. Targeting aberrant PI3K pathway signaling with XL147, a potent, selective and orally bioavailable PI3K inhibitor. AACR Meeting Abstracts 2007; (3_Molecular_Targets_Meeting): C205.
281. Laird AD. XL765 targets tumor growth, survival, and angiogenesis in preclinical models by dual inhibition of PI3K and mTOR. AACR Meeting Abstracts 2007; (3_Molecular_Targets_Meeting): B250.
282. Brana I, LoRusso P, Baselga J, et al. A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies. J Clin Oncol (Meeting Abstracts) 2010; 28(15_suppl): 3030.
283. Study of the safety and pharmacokinetics of XL147 in adults with solid tumors or lymphoma. Available at: http://www.clinicaltrials. gov/ct2/show/NCT00486135?term=XL147&rank=1 [accessed June 24, 2010].
284. Study of XL147 in advanced or recurrent endometrial cancer. Available at: http://www.clinicaltrials.gov/ct2/show/ NCT01013324?term=XL147&rank=5 [accessed June 24, 2010].
285. Study of the safety and pharmacokinetics of XL765 in adults with solid tumors. Available at: http://www.clinicaltrials.gov/ct2/show/ NCT00485719?term=XL765&rank=1 [accessed June 24, 2010].
286. Flinn IW, Byrd JC, Furman RR, et al. Preliminary evidence of clinical activity in a phase I study of CAL-101, a selective inhibitor of the p1108 isoform of phosphatidylinositol 3-kinase (P13K), in patients with select hematologic malignancies. J Clin Oncol (Meeting Abstracts) 2009; 27(15S): 3543.
287. Ikeda H, Hideshima T, Fulciniti M, et al. PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. Blood 2010; 116: 1460-8.
288. Herman SEM, Gordon AL, Wagner AJ, et al. The phosphatidylinositol 3-kinase-{delta} inhibitor CAL-101 demonstrates promising pre-clinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010; 116: 2078-88.
289. Dose escalation study of CAL-101 in select relapsed or refractory hematologic malignancies. Available at: http://www.clinicaltrials. gov/ct2/show/NCT00710528?term=CAL-101&rank=2 [accessed July 5, 2010].
290. Furman RR, Byrd JC, Flinn IW, et al. Interim results from a phase I study of CAL-101, a selective oral inhibitor of phosphatidylinositol 3-kinase p110d isoform, in patients with relapsed or refractory hematologic malignancies. J Clin Oncol (Meeting Abstracts) 2010; 28(15_suppl): 3032.
291. Study to investigate effects of CAL-101 in subjects with allergic rhinitis exposed to allergen in an environmental chamber. Available at: http://www.clinicaltrials.gov/ct2/show/ NCT0083691 4?term=CAL-101&rank=4. [accessed 5 July, 2010].
292. Sadhu C, Masinovsky B, Dick K, Sowell CG, Staunton DE. Essential role of phosphoinositide 3-kinase delta in neutrophil directional movement. J Immunol 2003; 170: 2647-54.
293. Billottet C, Grandage VL, Gale RE, et al. A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene 2006; 25: 6648-59.
294. Yaguchi S, Fukui Y, Koshimizu I, et al. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst 2006; 98: 545-56.
295. Kong D, Yamori T. ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms. Cancer Sci 2007; 98: 1638-42.
296. Kong D, Yaguchi S, Yamori T. Effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor, on DNA-dependent protein kinase. Biol Pharm Bull 2009; 32: 297-300.
297. Dan S, Yoshimi H, Okamura M, Mukai Y, Yamori T. Inhibition of PI3K by ZSTK474 suppressed tumor growth not via apoptosis but G0/G1 arrest. Biochem Biophys Res Commun 2009; 379: 104-9.
298. Kong D, Okamura M, Yoshimi H, Yamori T. Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor. Eur J Cancer 2009; 45: 857-65.
299. Berrie CP, Falasca M. Patterns within protein/polyphosphoinositide interactions provide specific targets for therapeutic intervention. FASEB J 2000; 14: 2618-22.
300. Piccolo E, Vignati S, Maffucci T, et al. Inositol pentakisphosphate promotes apoptosis through the PI 3-K/Akt pathway. Oncogene 2004; 23: 1754-65.
301. Razzini G, Berrie CP, Vignati S, et al. Novel functional PI 3-kinase antagonists inhibit cell growth and tumorigenicity in human cancer cell lines. FASEB J 2000; 14: 1179-87.
302. Maffucci T, Piccolo E, Cumashi A, et al. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects. Cancer Res 2005; 65: 8339-49.
303. Vallejo M, Jackson T, Lightman S, Hanley MR. Occurrence and extracellular actions of inositol pentakis-and hexakisphosphate in mammalian brain. Nature 1987; 330: 656-8.
304. Chen Q. Determination of phytic acid and inositol pentakisphosphates in foods by high-performance ion chromatography. J Agric Food Chem 2004; 52: 4604-13.
305. Falasca M, Chiozzotto D, Godage HY, et al. A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate. Br J Cancer 2010; 102: 104-14.
306. U.S. National Institutes of Health. Available at: http://www.clinicaltrials.gov/ [accessed June 23, 2010].
307. Arcaro A, Wymann MP. Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Biochem J 1993; 296: 297-301.
308. Powis G, Bonjouklian R, Berggren MM, et al. Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. Cancer Res 1994; 54: 2419-23.
309. Brunn GJ, Williams J, Sabers C, Wiederrecht G, Lawrence JC Jr., Abraham RT. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J 1996; 15: 5256-67.
310. Wymann MP, Bulgarelli-Leva G, Zvelebil MJ, et al. Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol Cell Biol 1996; 16: 1722-33.
311. Liu Y, Shreder KR, Gai W, Corral S, Ferris DK, Rosenblum JS. Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian polo-like kinase. Chem Biol 2005; 12: 99-107.
312. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994; 269: 5241-8.
313. Gharbi SI, Zvelebil MJ, Shuttleworth SJ, et al. Exploring the specificity of the PI3K family inhibitor LY294002. Biochem J 2007; 404: 15-21.
314. Knight ZA, Chiang GG, Alaimo PJ, et al. Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorg Med Chem 2004; 12: 4749-59.
315. Ihle NT, Paine-Murrieta G, Berggren MI, et al. The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol Cancer Ther 2005; 4: 1349-57.
316. Park S, Lee Y. Interleukin-17 regulation: an attractive therapeutic approach for asthma. Respir Res 2010; 11: 78.
317. Park SJ, Lee KS, Kim SR, et al. Phosphoinositide 3-kinase {delta} inhibitor suppresses IL-17 expression in a murine asthma model. Eur Respir J 2010 (in press).
318. Safety of TG100-115 for heart attack treated with angioplasty. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00103350?term=TG10 0-115&rank=1 [accessed June 23, 2010].
319. Sharma SV, Lee DY, Li B, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010; 141: 69-80.
320. Tan DS, Gerlinger M, Teh BT, Swanton C. Anti-cancer drug resistance: Understanding the mechanisms through the use of integrative genomics and functional RNA interference. Eur J Cancer 2010; 46: 2166-77.
321. Jimeno A., Herbst RS, Falchook GS, et al., Final results from a phase I, dose-escalation study of PX-866, an irreversible, panisoform inhibitor of PI3 kinase. J Clin Oncol (Meeting Abstracts) 2010; 28(15_suppl): 3089.
322. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66: 1500-8.
323. Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3Kdependent feedback loop in human cancer. J Clin Invest 2008; 118: 3065-74.
324. Workman P, Clarke PA, Raynaud FI, van Montfort RL. Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res 2010; 70: 2146-57.
325. Walker EH, Perisic O, Ried C, Stephens L, Williams RL. Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature 1999; 402: 313-20.
326. Huang CH, Mandelker D, Gabelli SB, Amzel LM. Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha. Cell Cycle 2008; 7: 1151-6.
327. Berndt A, Miller S, Williams O, et al. The p110delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. Nat Chem Biol 2010; 6: 244.
328. LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Update 2008; 11: 32-50.
329. Yao E, Zhou W, Lee-Hoeflich ST, et al. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin Cancer Res 2009; 15: 4147-56.
330. Engelman JA, Chen L, Tan X, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008; 14: 1351-6.
331. Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol 2008; 8: 393-412.
332. Knight ZA., Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 2010; 10: 130-7.
333. Yu K, Toral-Barza L, Shi C, Zhang WG, Zask A. Response and determinants of cancer cell susceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strategy. Cancer Biol Ther 2008; 7: 307-15.